A Phase II oncology trial screens 40 patients. Nine weeks later, 28 have failed. The coordinator is buried in manual chart reviews across multiple EHR systems while the sponsor calls for a performance review. This scenario plays out across the industry, where roughly 85% of trials face recruitment delays and screen failure rates range from 20% to over 70% depending on therapeutic area. The real problem is not unavoidable failures, it is catching disqualifying criteria too late.
The cost is measurable. Direct screening costs run about $1,200 per failure. A trial that screens 200 to enroll 80 with a 40% failure rate burns $96,000 before the first enrolled visit. Add the indirect costs: trial delays cost roughly $40,000 per day in Phase II or III direct costs, and up to $500,000 per day in lost drug sales for every week of enrollment slippage.
CTMS-connected pre-screening addresses this by structuring eligibility checks before consent, flagging high-prevalence failure criteria early, and surfacing enrollment analytics that manual spreadsheets cannot provide. When integrated with EHR pre-screening tools or FHIR-compatible eligibility engines, CTMS workflows can redirect coordinator time from repetitive chart review to patient communication, reduce late-stage disqualifications, and catch protocol design issues before they trigger amendments.